BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Institute of Biomedical Engineering (BME) - ECPv6.18.0//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:Institute of Biomedical Engineering (BME) X-ORIGINAL-URL:https://bme.utoronto.ca X-WR-CALDESC:Events for Institute of Biomedical Engineering (BME) REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/Toronto BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20210314T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20211107T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20220313T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20221106T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20230312T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20231105T060000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220920T120000 DTEND;TZID=America/Toronto:20220920T130000 DTSTAMP:20220919T195231Z CREATED:20220704T182645Z LAST-MODIFIED:20220919T195231Z UID:10000042-1663675200-1663678800@bme.utoronto.ca SUMMARY:Global Speaker Series: Gordon Fishell\, PhD – Harvard University DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. Medicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Gordon Fishell\, PhD\, Professor of Neurobiology\, Harvard Medical School and the Stanley Center at the Broad. The title of this talk will be\, “The intimate dependence and remarkable precision of cortical interneurons.” In Person – Register Here\nVirtual – Register Here\nHybrid event\, with in-person and virtual options\nIn-person will be held at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.\nVirtual event links will be sent after registration.\nMore About gordon fishell:\nProfessor Fishell teaches in the department of Neurobiology at Harvard Medical center and is an institute member of the Broad institute. He was previously the associate director of the New York University (NYU) Neuroscience Institute\, Julius Raines Professor of Neuroscience and Physiology at NYU\, and director of the graduate program in neuroscience and physiology at the NYU School of Medicine. Professor Fishell completed his Ph.D. in neurobiology from the University of Toronto and conducted postdoctoral research at Columbia University and the Rockefeller University. His laboratory is interested in how the architecture of brain circuits are assembled\, with a special focus on the diverse populations of inhibitory interneurons that are found in both pallial and subpallial telencephalon. Professor Fishell’s laboratory has spent the past 20 years working to understand the inhibitory cells that regulate excitatory signaling in the brain.\n Learn more about Gordon Fishell URL:https://bme.utoronto.ca/event/global-speaker-series-gordon-fishell-phd-harvard-university/ LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada CATEGORIES:External Speaker Series END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220916T123000 DTEND;TZID=America/Toronto:20220916T130000 DTSTAMP:20220915T212307Z CREATED:20220824T165250Z LAST-MODIFIED:20220915T212307Z UID:10000033-1663331400-1663333200@bme.utoronto.ca SUMMARY:Graduate Seminar Series: Molecular Stream - Mohamed Elsayed DESCRIPTION:Graduate Seminar Series: Molecular Stream\nGraduate Seminar Series for the Institute of Biomedical Engineering (BME). This day is for molecular stream presenters.\nIf you would like to invite your Principal Investigator\, please add their email via the ‘Add Guest’ button and they will also be notified of your presentation.\nPresentation Title: Towards automated cell isolation using Optoelectronic Tweezers and Digital Microfluidics\nAbstract:\nOptoelectronic tweezers uses patterned illumination to generate electric field gradients\, inducing dielectrophoretic forces that can move objects.\nI will introduce light-driven micromotors and micromachines based on optoelectronic tweezers. Using a circular micro-gear as a unit component\, we demonstrate a range of new functionalities\, including a touchless micro- feed-roller that allows the programming of precise three-dimensional particle trajectories\, multi-component micro-gear trains that serve as torque- or velocity-amplifiers\, and micro- rack-and-pinion systems that serve as microfluidic valves.\nI will present the utility of this technique in a biological application through a project “Autonomous control of optoelectronic microrobots for brain stem cell isolation”. There are various exciting research questions in the field of neuroscience that require harvesting stem cells from mouse brains. Current methods for harvesting stem cells have poor yield and often require pooling cells from various mice\, placing serious limitations on the type of research. We explored using the optoelectronic micro-robot to harvest stem cells from primary dissection cell suspensions. These are sensitive cells so they benefit strongly from the gentle approach offered by the optoelectronic micro-robot.\nI will then switch gears to present work done to date in another project using digital microfluidics “Automated processing of sexual assault samples to enable rapid DNA analysis”. Sexual assault samples contain DNA from multiple sources\, making them one of the most challenging types of forensic samples to analyze\, often beyond the reach of rapid DNA analyzers. The goal of this project is to develop a workflow that facilitates the use of rapid DNA typing instruments for sexual assault samples.\nSupervisor Name: Aaron Wheeler\nYear of Study: 5\nProgram of Study: PhD\nZoom link: https://us02web.zoom.us/j/89610372821?pwd=azd4SCtYVWtreVovaGNPV1c2NGY2Zz09\nMeeting ID: 896 1037 2821\nPassword: 483329\nPowered by Calendly.com URL:https://bme.utoronto.ca/event/graduate-seminar-series-molecular-stream-mohamed-elsayed/ CATEGORIES:Graduate Seminar Series END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220915T120000 DTEND;TZID=America/Toronto:20220915T123000 DTSTAMP:20220914T210730Z CREATED:20220824T165250Z LAST-MODIFIED:20220914T210730Z UID:10000034-1663243200-1663245000@bme.utoronto.ca SUMMARY:Graduate Seminar Series: Cell and Tissue Stream - Aaron Rosenstein DESCRIPTION:Graduate Seminar Series: Cell and Tissue Stream\nGraduate Seminar Series for the Institute of Biomedical Engineering (BME). This day is for cell and tissue stream presenters.\nIf you would like to invite your Principal Investigator\, please add their email via the ‘Add Guest’ button and they will also be notified of your presentation.\nPresentation Title: Recording cellular histories in DNA with prime editing\nAbstract: Recording cellular stimuli into DNA has been a common aspiration of synthetic biologists for the purposes as both a research tool and eventual clinical diagnostic application. Whether as a means of understanding interactions on the single-cell level\, or reconstructing histories of cellular events\, a cellular DNA recording device has widespread utility. Previous attempts at building a robust recorder\, however\, have fallen short on this goal. Here I present steps taken towards developing a recording device which can incorporate sequential analog signals of events into genomic DNA. This device will leverage prime editing as a means of integrating signals encoded on prime editing guide RNAs (pegRNAs) into a specific region of the genome termed recording loci\, while pegRNA expression will be induced by the magnitude of signals respectively. I envisage a mechanism whereby repeated prime editing can construct an organized cellular record of event histories. Development of this device requires empirical identification of the sequence-determinants of effective prime editing\, as well as constructs for translation of diverse cellular signals into pegRNA messages of commensurate magnitude. Preliminary results indicate a baseline for recording synthetic signals in this manner. Ultimately this project will yield a robust recording device which can meet investigator’s needs\, and can hopefully be adopted as both a research tool and clinical diagnostic device.\nSupervisor Name: Dr. Michael Garton\nYear of Study: 2\nProgram of Study: PhD\nZoom link: https://us02web.zoom.us/j/89610372821?pwd=azd4SCtYVWtreVovaGNPV1c2NGY2Zz09\nMeeting ID: 896 1037 2821\nPassword: 483329\nPowered by Calendly.com URL:https://bme.utoronto.ca/event/graduate-seminar-series-cell-and-tissue-stream-aaron-rosenstein/ CATEGORIES:Graduate Seminar Series END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220914T120000 DTEND;TZID=America/Toronto:20220914T130000 DTSTAMP:20220913T193731Z CREATED:20220909T192346Z LAST-MODIFIED:20220913T193731Z UID:10000049-1663156800-1663160400@bme.utoronto.ca SUMMARY:Careers Beyond Academia - Laura Smith\, PhD Principal Scientist\, AmacaThera and Stephanie Fisher\, PhD Senior Scientist\, BlueRock Therapeutics DESCRIPTION:About the series\nTo what extent can we plan and design our careers? How much depends on our environment\, the choices we make\, the opportunities that present themselves\, the networks we build\, and the achievements and failures we experience along the way? Medicine by Design and Stem Cell Network have partnered to host Careers Beyond Academia\, a virtual career seminar series that will profile a wide variety of different careers available to trainees who hold a degree in the life sciences. The goal of the series is to help trainees understand the different careers available outside of academia\, the skills required for certain positions\, and some of the daily functions of those positions.\nVirtual Event – Register Here\nSpeakers:\nLaura Smith\, PhDPrincipal Scientist\, AmacaThera\nStephanie Fisher\, PhDSenior Scientist\, BlueRock Therapeutics\nEach session will feature two speaker presentations that will be recorded and available on both Medicine by Design and Stem Cell Network’s website and YouTube channel. Trainees will be able to participate in a joint Q&A and panel discussion during the session.\n  URL:https://bme.utoronto.ca/event/careers-beyond-academia-laura-smith-phd-principal-scientist-amacathera-and-stephanie-fisher-phd-senior-scientist-bluerock-therapeutics/ LOCATION:Virtual CATEGORIES:External Speaker Series END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220913T120000 DTEND;TZID=America/Toronto:20220913T130000 DTSTAMP:20220901T132242Z CREATED:20220606T143441Z LAST-MODIFIED:20220901T132242Z UID:10000030-1663070400-1663074000@bme.utoronto.ca SUMMARY:Invited Academic Seminar Series – Ehsan Hoque- Embedding human values in digital medicine (Hybrid Delivery) DESCRIPTION:Speaker\nEhsan Hoque\nAssociate Professor\nComputer Science\nUniversity of Rochester \n\nAbstract\nMany argue that making interoperability\, federal incentives\, barcoding\, and deep learning is the core of revolutionizing healthcare information technology. It is. But it is also about developing technologies that align with our values and integrate effortlessly with our lifestyles and healthcare workflow while improving access and equity. \nIn this talk\, I will highlight the following projects and their design principles\, technical contributions\, and a roadmap to integrating them within the existing healthcare workflow. \n1)      How to develop an automated screening and tracking of Parkinson’s disease—the fastest-growing neurological disability —through a series of tasks on a webcam anytime\, anywhere? \n2)      How can AI assist doctors in improving empathy and listening skills as they help terminally ill patients make critical decisions? \n3)      How can virtual avatars with standardized\, repeatable\, and objective feedback improve the social skills of individuals who struggle with socio-emotional communication\, such as those with Autism? \nAlong with technical contributions\, I will reflect on the journey of how a trained computer scientist like myself could get into healthcare research driven by personal circumstances and enabled by excellent collaborators. \nBio: Ehsan Hoque is an associate professor of computer science at the University of Rochester\, where he co-leads the Rochester Human-Computer Interaction (ROC HCI) Group. From 2018-2019\, he was also the Interim Director of the Goergen Institute for Data Science. Ehsan earned his Ph.D. from MIT in 2013\, where the MIT Museum highlighted his dissertation—the development of an intelligent agent to improve human ability — as one of MIT’s most unconventional inventions. Building on the work/patent\, Microsoft released “Speaker Coach” available in PowerPoint. Ehsan is best known for introducing and extensively validating the idea of using AI to train and enhance elements of basic human ability. \nEhsan and his students’ work has been recognized by NSF CAREER Award\, MIT TR35\, Young Investigator Award by the US Army Research Office (ARO). In 2017\, Science News named him one of the 10 scientists to watch\, and in 2020\, the National Academy of Medicine recognized him as one of the emerging leaders in health and medicine. Ehsan is blessed to be the primary caregiver of his younger brother\, 22\, who is nonverbal and diagnosed with Autism and down syndrome. \n\nHost\nLueder Kahrs URL:https://bme.utoronto.ca/event/invited-academic-seminar-series-ehsan-hoque/ LOCATION:MS3153 ATTACH;FMTTYPE=image/jpeg:https://bme.utoronto.ca/wp-content/uploads/2022/06/Hoque-Ehsan-Nov-2021-LR.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220825T113000 DTEND;TZID=America/Toronto:20220825T123000 DTSTAMP:20220816T175930Z CREATED:20220816T175846Z LAST-MODIFIED:20220816T175930Z UID:10000002-1661427000-1661430600@bme.utoronto.ca SUMMARY:User-Programmable Hydrogel Biomaterials to Probe and Direct 4D Stem Cell Fate DESCRIPTION:Special Seminar \nDate: Thursday August 25\, 2022 Time: 11:30am – 12:30pm Location: Donnelly Centre \n160 College Street\, 2nd Floor\, Red Seminar Room \nDr. Cole A. DeForest\, PhD University of Washington \n\nAbstract \nThe extracellular matrix directs stem cell function through a complex choreography of biomacromolecular interactions in a tissue-dependent manner. Far from static\, this hierarchical milieu of biochemical and biophysical cues presented within the native cellular niche is both spatially complex and ever changing. As these pericellular reconfigurations are vital for tissue morphogenesis\, disease regulation\, and healing\, in vitro culture platforms that recapitulate such dynamic environmental phenomena would be invaluable for fundamental studies in stem cell biology\, as well as in the eventual engineering of functional human tissue. In this talk\, I will discuss some of our group’s recent successes in reversibly modifying both the chemical and physical aspects of synthetic cell culture platforms with user-defined spatiotemporal control\, regulating cell-biomaterial interactions through user- programmable Boolean logic\, and engineering microvascular networks that span nearly all size scales of native human vasculature (including capillaries). Results will highlight our ability to modulate intricate cellular behavior including stem cell differentiation\, protein secretion\, and cell-cell interactions in 4D. \nBiography \nDr. Cole A. DeForest is the Weyerhaeuser Endowed Associate Professor in the Departments of Chemical Engineering and Bioengineering\, the Associate Chair of Chemical Engineering\, as well as a core faculty member of the Institute for Stem Cell & Regenerative Medicine at the University of Washington (UW) where he began in 2014. He received his B.S.E. degree from Princeton University in 2006\, majoring in Chemical Engineering and minoring in Material Science Engineering and Bioengineering. He earned his Ph.D. degree under the guidance of Dr. Kristi Anseth from the University of Colorado in Chemical and Biological \nEngineering with an additional certificate in Molecular Biophysics. His postdoctoral research was performed with Dr. David Tirrell in the Divisions of Chemistry and Chemical Engineering at the California Institute of Technology. He has published >60 peer-reviewed articles\, including as the corresponding author for those appearing in Nature Materials\, Nature Chemistry\, Advanced Materials\, JACS\, PNAS\, Science Advances\, and Nature Reviews Materials. Dr. DeForest has received numerous research awards and honors including the Society for Biomaterials Young Investigator Award (2020)\, NIH Maximizing Investigators’ Research Award (MIRA R35\, 2020)\, Safeway Early Career Award (2018)\, NSF CAREER Award (2017)\, AIChE 35-Under-35 Award (2017)\, ACS PMSE Young Investigator Award (2017)\, Jaconette L. Tietze Young Scientist Award (2015)\, Biomedical Engineering Society Student Fellow Award (2013)\, DSM Polymer Technology Award (2011)\, ACS Excellence in Graduate Polymer Research Award (2010)\, MRS Graduate Student Research Gold Award (2009)\, Society for Biomaterials Outstanding Achievement Award (2009)\, Princeton University Material Science Student of the Year (2006)\, Princeton University Most Approachable Resident Adviser (2005)\, and Boulder High School Valedictorian (2002). Notably\, he has also been recognized for excellence in teaching and was awarded the UW Presidential Distinguished Teaching Award (2016)\, given annually to a single Assistant Professor across all of the UW. His research has been supported through fellowships and grants from the National Science Foundation\, the National Institutes of Health\, and the US Department of Education. URL:https://bme.utoronto.ca/event/user-programmable-hydrogel-biomaterials-to-probe-and-direct-4d-stem-cell-fate/ LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada CATEGORIES:External Speaker Series ORGANIZER;CN="Molly Shoichet":MAILTO:adminshoichet@utoronto.ca END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20220808 DTEND;VALUE=DATE:20220809 DTSTAMP:20220623T133551Z CREATED:20220623T133551Z LAST-MODIFIED:20220623T133551Z UID:10000045-1659916800-1660003199@bme.utoronto.ca SUMMARY:Entrepreneurship for Cardiovascular Health Opportunities (ECHO): CALL FOR APPLICATIONS DESCRIPTION:Entrepreneurship for Cardiovascular Health Opportunities (ECHO): CALL FOR APPLICATIONS \n  \nTo reach teams across Canada\, ECHO is a fully virtual program. \n  \nWe are pleased to announce a call for applications for the 2022-2023 ECHO program! \n\nFounded in 2018\, ECHO is a 12-month online training program led by veteran entrepreneurs and high-calibre consultants across a variety of sectors. Comprised of a unique combination of five complementary modules\, ECHO provides innovators of cardiovascular technologies with entrepreneurship training\, mentorship\, and networking opportunities\, and the chance to pitch for start-up funding from a $250\,000 pool. \n\nPlease see the attached brochure. You can also visit our webpage at https://tedrogersresearch.ca/ECHO/ for program details\, instructions and application forms. Applications are due Monday\, August 8\, 2022. \n\nIf you have any questions regarding ECHO\, please contact Soror Sharifpoor (soror.sharifpoor@utoronto.ca). \n\nECHO is organized and funded by the Translational Biology and Engineering Program (TBEP) – the University of Toronto component of the Ted Rogers Centre for Heart Research – in partnership with the Health Innovation Hub (H2i)\, a University of Toronto campus-linked accelerator. URL:https://bme.utoronto.ca/event/entrepreneurship-for-cardiovascular-health-opportunities-echo-call-for-applications/ CATEGORIES:Events & Workshops ORGANIZER;CN="Translational Biology and Engineering Program (TBEP)":MAILTO:reception.tbep@utoronto.ca END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220721T100000 DTEND;TZID=America/Toronto:20220721T110000 DTSTAMP:20220719T155334Z CREATED:20220719T155334Z LAST-MODIFIED:20220719T155334Z UID:10000039-1658397600-1658401200@bme.utoronto.ca SUMMARY:Nanomedicines for the Research\, Detection\, and Treatment of Cancer and Allied Diseases DESCRIPTION:Date: Thursday July 21\, 2022 \nTime: 10:00am – 11:00am \nLocation: Donnelly Centre \n160 College Street\, 2nd Floor\, Red Seminar Room \n  \nDr. Daniel A. Heller\, PhD Cornell University \n  \nAbstract \nWe develop nanotechnologies to accelerate the research\, diagnosis\, and treatment of cancer and allied diseases. We focus on nanoparticle drug delivery systems and nanosensor-based diagnostics and drug discovery tools. \nTo build better cancer therapeutics\, we investigate the potential to improve the therapeutic index of precision medicines via nanomedicine-based strategies to localize drugs to tumors using vascular targets. We developed machine learning processes to facilitate the encapsulation of diverse drug classes into these nanoparticles\, based on drug molecular structure\, resulting in the rapid synthesis of many\, diverse\, targeted nanotherapeutics. We found that P-selectin\, expressed endogenously on activated endothelium in tumors\, can be used as a nanotherapeutic target improve the efficacy of kinase inhibitors and abrogate dose-limiting toxicities\, to improve therapeutic index. P-selectin can also be induced via ionizing radiation\, enabling the enhancement of the target. We also found that endothelial targeting can improve delivery across intact blood-brain barrier for the treatment of intracranial tumors and metastases\, via activating transendothelial transport. \nWe also develop optical nanosensor technologies using carbon nanotubes to facilitate longitudinal detection of cancer biomarkers\, and to build new assays for cancer drug development. These technologies employ the bandgap fluorescence of single-walled carbon nanotubes (SWCNTs) which emit in the near-infrared “tissue transparent” window and can respond to analytes down to the single-molecule level. We have developed new sensors for the detection of metabolic changes in live cells and tissues\, disease biomarkers in situ via implants\, and overall disease states\, aided by machine learning processes. \nBiography \nDr. Daniel A. Heller\, PhD\, is Head of the Cancer Nanomedicine Laboratory\, Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chair\, an Associate Member in the Molecular Pharmacology Program at Memorial Sloan-Kettering Cancer Center\, an Associate Professor in the Department of Pharmacology at Weill Cornell Medicine\, and a member of the Graduate Field Faculty in the Meinig School of Biomedical Engineering at Cornell University. His \nwork focuses on the development of nanoscale technologies for the treatment\, diagnosis\, and research of cancer. Dr. Heller obtained his PhD in chemistry from the University of Illinois at Urbana-Champaign in 2010\, working in the laboratory of Michael Strano. He completed a Damon Runyon Cancer Research Foundation Postdoctoral Fellowship in the laboratory of Robert Langer at the David H. Koch Institute for Integrative Cancer Research at MIT in 2012. He is a 2012 recipient of the National Institutes of Health Director’s New Innovator Award\, a 2015 Kavli Fellow\, a 2017 recipient of the Pershing Square Sohn Prize for Young Investigators in Cancer Research\, a 2018 American Cancer Society Research Scholar\, a 2018 recipient of the CRS Nanomedicine and Nanoscale Drug Delivery Focus Group Junior Faculty Award\, a 2018 NSF CAREER Awardee\, a 2020 awardee of the Weill Cornell Graduate School Pharmacology Teaching and Mentoring Award\, and a 2021 American Institute for Medical and Biological Engineering (AIMBE) Fellow. \n\nHosted by Dr. Molly Shoichet \nSnacks and refreshments will be served URL:https://bme.utoronto.ca/event/nanomedicines-for-the-research-detection-and-treatment-of-cancer-and-allied-diseases/ LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada CATEGORIES:External Speaker Series END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220710T130000 DTEND;TZID=America/Toronto:20220710T160000 DTSTAMP:20220628T150838Z CREATED:20220628T150838Z LAST-MODIFIED:20220628T150838Z UID:10000043-1657458000-1657468800@bme.utoronto.ca SUMMARY:TERMIS-AM/ NSERC CREATE Training Program in Organ-on-a-Chip Engineering and Entrepreneurship Per-conference Workshop DESCRIPTION:https://toep.utoronto.ca/ \nNSERC CREATE Training Program in Organ-on-a-Chip & Entrepreneurship (TOeP) is organizing a pre-conference workshop geared towards inspiring trainees to engage into a process of taking their discovery out of the lab and into the real world. \n  \nUniquely\, our workshop speakers were all (or still are) trainees who haven commercialized the discoveries from their PhD or Post-doctoral training through a start-up company. They were instrumental in growing these companies and have valuable lessons to share to facilitate the journey. \n  \nAt the end of this workshop\, you will be able to: understand how to identify the novel components of your work\, improve problem-based design in tissue engineering and regenerative medicine\, understand the steps toward commercialization of devices and cell based therapeutics and what elements to include in a successful pitch. \n  \nNSERC CREATE TOeP Training program will reimburse the workshop registration fee for the first 30 trainees who register. Reimbursement forms will be available at the workshop. \n  \nProgram: \nSunday July 10th\, 2022 \n1:00PM-1:20PM      Milica Radisic\, Professor and Canada Research Chair (Tier 1) in Organ-on-a-Chip Engineering\, University of Toronto; Senior Scientist\, Toronto General Research Institute; Director\, NSERC CREATE Training Program in Organ-on-a-Chip Engineering and entrepreneurship. www.radisiclab.com \n“Introduction to the goals of the workshop” \n  \n1:20PM-1:40PM      Anis Hadjenni- CEO and Co-founder\, Rheolution Inc\, https://rheolution.com/ \n“From an idea to a successful company- the story of Rheolution”                                                               \n1:40PM-2:00PM      Wendy Neimark\, Co-founder and Chief Technology Officer\, Ripple Therapeutics\, www.rippletherapeutics.com \n“Assessing the novelty of your idea\, the story of Ripple”                                                               \n2:00PM-2:20PM      Milica Vukmirovic\, Director of External Programs & Partnerships\, Precision Medicine Initiative\, PRiME\, University of Toronto\, https://www.prime.utoronto.ca/ \n“Developing a pitch and setting your idea for successful fundraising”                                                              \n2:20PM-3:00PM      Networking break \n  \n3:00PM-3:20PM      Sepand Bafti\, Director of Biological Science at Nortis \n “Working to grow your organ-on-a-chip startup”          https://nortisbio.com/                                                             \n3:20PM-3:40PM      Dawn Lin\, PhD Candidate at McMaster University & Co-founder Organo-Biotech\, https://www.organo-biotech.com/ \n“Trainee perspective- starting a company during your PhD”                                                                        \n3:40PM-4:00PM      Mohsen Akbari\, Associate Professor\, University of Victoria\, https://www.uvic.ca/ecs/mechanical/faculty-and-staff/faculty/makbari.php \n“PI perspective on starting a company from the lab”                                                 \n  \nAbout NSERC CREATE TOeP: \nThe long-term objective of TOeP is to educate skilled individuals with expertise in both bioengineering and entrepreneurship\, and enable personal development of our students so that they can ultimately fuel the creation of a high-tech economy. \nTOeP provides specific workshops for Professional Skill Training in the following categories: Pitching and public speaking; IP Law; Entrepreneurship; Networking and business etiquette; Teamwork\, critical thinking\, leadership & project management; Business and Finance.  TOeP provides technical training through an Organ-on-a-Chip Course\, TOeP specific guest speaker seminars and Ontario-on-a-Chip/TOeP Annual Symposium which features a TOeP student pitch competition. \nTOeP provides coaching to the students for pitch development and practice sessions to perfect those. To reach a broader scientific community TOeP also organizes the Entrepreneurship Workshop at the meetings such as this one. \nTOeP trainees are required to complete exchanges with other academic labs\, in order to satisfy the mobility required for the program\,  shadow entrepreneurs\, develop their device prototypes and fundraise for commercialization of their prototypes either via VCs\, angels and private investors or through grants. URL:https://bme.utoronto.ca/event/termis-am-nserc-create-training-program-in-organ-on-a-chip-engineering-and-entrepreneurship-per-conference-workshop/ CATEGORIES:Events & Workshops END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20220710 DTEND;VALUE=DATE:20220714 DTSTAMP:20220510T202455Z CREATED:20220510T202455Z LAST-MODIFIED:20220510T202455Z UID:10000010-1657411200-1657756799@bme.utoronto.ca SUMMARY:2022 TERMIS-AM Conference DESCRIPTION:SUBMIT YOUR ABSTRACT HERE\n\n\n\nThe TERMIS-AM 2022 Conference will feature an outstanding scientific program bringing together national and international communities of scientists\, clinicians\, industry leaders\, post-doctoral fellows\, graduate students\, entrepreneurs\, and representatives of government funding agencies engaged in the fields of tissue engineering and regenerative medicine. \nPlease note\, there is no fee or charge to submit an abstract. \nIf you’ve submitted an abstract with TERMIS-AM before\, please use the same login information. You will need to make an account if you are new to the abstract system. \nClick HERE for COVID-19 Information \nAbstract Consideration\nExperts from academia\, industry and government are invited to present timely research to successful implementation of technologies in all areas of tissue engineering/regenerative medicine. \nNote: All abstract submitters including presenting authors are expected to pay their own travel expenses and conference registration fee(s). \nSUBMISSION INSTRUCTIONS \nAbstract Preparation\nAuthors must submit their abstract electronically. This is the ONLY option for abstract submission. \nTitle: Title should be brief\, clearly indicating the nature of the presentation. Title should be in bold font and mixed case font followed by a single return. Do not put a period at the end of the title.\nExample: This is a Properly Formatted Abstract Title \nCategory: Please select the TWIG category that your abstract falls under. You can select your primary\, secondary\, and tertiary preference for categories\, but only one is required. \nCategories: Please note sessions are slotted based on the number of abstracts submitted. \nBiofabrication & Bioreactors – TWIG\n+ Biofabrication and Software Tools in TERM\n+ Bioreactors and Organs-on-chips in TERM\n+ 3D Bioprinting Methods and Applications\nCardiovascular/Angiogenesis/Blood – TWIG\n+ Biomaterials for Endogenous Cardiovascular Repair\n+ Engineering Microvasculature for Tissue Regeneration\n+ Cell-based Approaches to Cardiac Regeneration & Repair\nCommercialization & Regulation – TWIG\n+ Regenerative Medicine Applications to Organ Transplantation Medicine\nDental & Craniofacial – TWIG\n+ Tissue Engineering Solutions for Craniofacial Regeneration\nImaging and Assessment – TWIG\n+ Non-invasive Imaging and Analysis of Engineered Tissues\nMusculoskeletal – TWIG\n+ ECM Technologies in Musculoskeletal Repair\n+ Regenerative Rehabilitation: Integrating Mechanical Stimulation with TERM\n+ Articular Cartilage Bioengineering & Regeneration\n+ Strategies for Regeneration of Complex Muscle Defects\nNeural & Spine – TWIG\n+ Frontiers in Spatiotemporal Control for Neural Tissue Engineering\nOphthalmologic – TWIG\n+ Cell Therapeutic Approaches for Retinal Degenerative Diseases\nRespiratory\, Urologic & Gastrointestinal – TWIG\n+ Respiratory\, Urologic\, & Gastrointestinal Tissue Engineering\n+ Tissue Repair for Voiding Dysfunction and Pelvic Floor Disorders\nScaffolds\, Matrices\, and Biomaterials – TWIG\n+ Biomaterials to Direct Stem Cell Fate\n+ Biomaterials for Women’s Health in Tissue Engineering\n+ Biomaterials and Immunomodulation\n+ Bio-metals Mediated Tissue Regeneration\n+ Nature as a Source of TERM Biomaterials and Strategies\n+ Bioactive Biomaterials for Soft Tissue Engineering\nStem Cells & Cell Therapies & Developmental Biology and Cell Signaling – TWIG\n+ Stem Cells & Cell Therapies\, Dev Bio\, and Cell Signaling\n+ Regeneration in the Context of Aging\nSkin\, Wound Healing\, and Inflammation – TWIG\n+ Skin\, Wound Healing\, and Inflammation\nOther\n+ 3D Tissue -Engineered Cancer/Disease Modeling and Organoids Part 1 & 2 \nAuthors: This is where you will enter your authors and it will be separate from your abstract body. Please enter information in the fields provided and the system with format it for you automatically. Complete contact information (name\, mailing address\, and e-mail) for each author listed on the abstract must be entered before submitting the abstract file. \nDisclosure Information: Submitting disclosures is a step when entering abstract authors. It will be the same step under each individual speaker. In order for your colleagues to properly evaluate the information\, analysis and opinions presented in your abstract\, it is important that they be informed of potential conflicts of interest pertinent to the research submitted. Therefore\, conference management requires that all authors provide any relevant information concerning personal or professional circumstances and relationships that might reasonably be expected to affect the author’s view on the subject. Examples include\, but are not limited to: \n+Stock options or bond holdings in a for-profit corporation or self-directed pension plan\n+Employment (full or part-time)\n+Ownership or partnership\n+Consulting fees or other remuneration (payment)\n+Non-remunerative positions of influence such as officer\, board member\, trustee\, or public spokesperson\n+Receipt of royalties\n+Speakers bureau \nAppropriate disclosure will be stated in the scientific program and the abstract volume. If you do not have anything to disclose\, you must indicate this on the online abstract submission form. The disclosure information you provide will not influence the review of your abstract. Abstracts will not be reviewed without proper completion of the disclosure section on the abstract submission form. Disclosure information for all authors is required upon abstract completion. \nAbstract: The abstract should clearly describe the nature of the research and the problem it addresses and be presented in such language as to be understood by scientists representing the multi-disciplinary nature of tissue engineering. The abstract should summarize the purpose/objective of the research\, the methodology employed\, the results\, and the conclusion/significance and will be split into these four categories. \n\nThe abstract length is limited to 500 words total across all four sections. These areas should not include authors\, disclosures\, or references.\nPlease no figures or tables in the abstract.\nReferences and acknowledgements are not needed in this abstract process.\n\nPresentation Preference: Please choose your preferred method of presentation (Oral\, Poster\, or Oral or Poster) where indicated. Your preference will be noted by the reviewers. Final determination will be made by the Program Planning Committee. \nPublication: Abstracts this year will be published on the TERMIS-AM website or in the journal. Here you can choose to opt-out of publication. \nDemographics: You can select if you are a Student or Young Investigator here. Please fill out the other demographic information if you feel comfortable. These questions help us promote diversity within our abstract presenters. \nReview My Work: Here you will see a green check mark if all steps have been completed or not and you will have to go back and make edits. Your submission is not complete unless you see a green check mark. You are able to make edits to your abstract until the deadline of January 12\, 2021\, 11:59 PM Pacific Time. Once the abstract deadline has passed\, no further edits can or will be made to an abstract. \nAbstract Withdrawals \nIf the abstract must be withdrawn\, the TERMIS-AM office must be notified in writing at least ONE month prior to the meeting via e-mail to Tatiana Veres at am2022@termis.org \nNOTE: ALL PRESENTERS ARE EXPECTED TO COVER THEIR OWN TRAVEL AND LODGING EXPENSES AND PAY THE CONFERENCE REGISTRATION FEES. \nRegistration Requirements \nAccepted authors are expected to pay their own travel expenses and conference registration fee(s). Dates of presentation cannot be guaranteed. \n\nSUBMIT YOUR ABSTRACT HERE\n\nFor More Information \nFor more information on abstract content\, format and submission procedure\, contact: \nTatiana Veres\nAssociate Meeting Manager\nam2022@termis.org URL:https://bme.utoronto.ca/event/2022-termis-am-conference/ CATEGORIES:Events & Workshops END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220707T140000 DTEND;TZID=America/Toronto:20220707T150000 DTSTAMP:20220624T151521Z CREATED:20220624T143324Z LAST-MODIFIED:20220624T151521Z UID:10000006-1657202400-1657206000@bme.utoronto.ca SUMMARY:Faculty Search Candidate Talk - Unconventional Nanobiophotonics: Upconversion/Persistent Luminescence Nanoparticles for Anti-cancer Therapy DESCRIPTION:Kai Huang\, PhD \nDepartment of Biochemistry and Molecular Biotechnology\nUniversity of Massachusetts Chan Medical School \nAbstract: Biophotonics has been widely applied as versatile and powerful approaches for biomedical applications\, such as for bioimaging\, biodetection\, photodynamic therapy\, and optogenetics. However\, conventional biophotonics suffers from several constraints. For example\, the short-wavelength excitation light cannot penetrate deep into the tissue\, thus requiring an invasive light delivery system for deep-tissue photodynamic therapy or optogenetics. In addition\, luminescence signal is interfered with autofluorescence noise\, bringing difficulties for high-quality bioimaging and biodetection. Here\, we address these issues by developing unconventional nanobiophotonics\, where we apply upconversion or persistent luminescence nanoparticles for anti-cancer therapy. Upconversion nanoparticles (UCNPs) convert near-infrared (NIR) excitation into short-wavelength visible light emission and thus serve as the light-transducer to bring deep tissue penetration NIR excitation for wireless photoactivations. We applied versatile nanoengineering approaches to produce UCNPs with controllable size/morphology\, tunable and enhanced luminescence\, and desirable biofunctionalizations. These UCNPs were applied for NIR-optogenetic control of CAR-T cell immunotherapy. We demonstrated that by wirelessly and spatiotemporally controlling the CAR-T cell activity\, we can achieve effective and safer immunotherapy of cancer\, overcoming the safety issue of conventional CAR-T immunotherapy. Persistent luminescence nanoparticles (PLNPs) are unique nanomaterials that emit long-lasting afterglow after excitation stops. PLNPs are significant for bioimaging by avoiding the autofluorescence induced by real-time excitation. We have developed the bottom-up syntheses of PLNPs with fine control of their energy traps\, heterostructures\, and energy accepting from dye-sensitizations\, contributing to enhanced persistent luminescence. We have demonstrated that PLNPs with enhanced luminescence are excellent for ultrasensitive imaging-guided tumor surgery. In addition\, we also demonstrated that by developing X-ray-excitable PLNPs\, we can achieve X-ray-photodynamic therapy with limitless tissue penetration and enhanced tumor eradication. URL:https://bme.utoronto.ca/event/faculty-search-candidate-talk-2/ LOCATION:Medical Sciences Building 3154\, 1 King's College Cir\, Toronto\, Ontario\, M5S 1A8\, Canada CATEGORIES:BME Faculty Search END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220706T100000 DTEND;TZID=America/Toronto:20220706T110000 DTSTAMP:20220624T145508Z CREATED:20220624T145430Z LAST-MODIFIED:20220624T145508Z UID:10000044-1657101600-1657105200@bme.utoronto.ca SUMMARY:Conversations in Convergence: Jesse Gillis\, PhD\, and Alaura Androschuk DESCRIPTION:Note: We are excited to transition Conversations in Convergence from a virtual to an in-person event\, providing more opportunity for networking and potential collaboration. \nJoin us for our Conversations in Convergence series\, which features interactive discussions between Medicine by Design researchers who study similar questions using different approaches. \nThe theme of this conversation will be\, “Immune modulation by extrinsic and environmental factors.”\nRegister now \nSpeakers\nAlaura Androschuk \, PhD candidate in Michael Sefton’s lab\, Institute of Biomedical Engineering and the Department of Chemical Engineering & Applied Chemistry. \nIdentifying signalling pathways underlying biomaterial-driven terminal axon growth using single nucleus RNA-sequencing\nAlaura Androschuk is a PhD candidate focusing on the use of biomaterials for endogenous repair of tissues\, specifically subcutaneous nerve regeneration. Under the supervision of  Michael Sefton\, she has focused in part on identifying the signalling pathways and cells underlying the biomaterial-driven repair of complex tissues using proteomics and single nucleus transcriptomics. \nJesse Gillis\, Associate Professor and Bassingthwaighte Chair in Integrative Physiology\, Department of Physiology\, University of Toronto. \nBuffered and unbuffered cell lineage variability\nJesse Gillis completed his undergraduate in Biophysics at the University of Toronto\, where he also received his PhD in Neuroscience in 2007. His post-doctoral training was done at the Centre for High-throughput Biology at UBC. There\, he focused on meta-analysis of expression data\, and particularly co-expression analysis\, which infers functionality between genes based on shared expression profiles\, a form of network analysis. Jesse joined the faculty of CSHL in 2012 with a central focus on improving network analysis. In 2017\, he was promoted to Associate Professor at CSHL with his work focusing on single cell analysis\, particularly in collaboration with researchers in the BRAIN Initiative Cell Census Network. In 2022\, Jesse returned to U of T as the inaugural Bassingthwaighte Chair in Integrative Physiology and a Medicine by Design investigator. \nAbout Conversations in Convergence\nThe goal is to foster cross-disciplinary discussions in support of convergence\, which is the integration of approaches from engineering\, science\, medicine and other fields to expand knowledge and spark innovation. The researchers will discuss how their unique perspectives\, knowledge and ideas inform their work\, and how their diverse approaches intersect and complement one another to advance regenerative medicine. URL:https://bme.utoronto.ca/event/conversations-in-convergence-jesse-gillis-phd-and-alaura-androschuk/ LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada CATEGORIES:External Speaker Series END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220623T130000 DTEND;TZID=America/Toronto:20220623T140000 DTSTAMP:20220609T150225Z CREATED:20220609T144131Z LAST-MODIFIED:20220609T150225Z UID:10000001-1655989200-1655992800@bme.utoronto.ca SUMMARY:Faculty Search Candidate: Designer polymer excipients to enable next-generation insulin formulations DESCRIPTION:Caitlin Maikawa\, PhD\nAbstract: Insulin was first isolated a century ago\, yet commercial formulations of insulin for hormone replacement therapy fall short of mimicking the endogenous glycemic control that occurs in non-diabetic individuals. Moreover\, diabetes management is increasingly relying on automated insulin delivery using closed-loop systems to improve glucose management and reduce patient burden. However\, improvements in insulin formulations\, sensors\, and algorithms are required to shift from hybrid systems to fully autonomous delivery. Insulin formulations that better mimic secretion from the beta-cells\, by enabling more rapid insulin absorption kinetics and/or co-delivering complementary hormones (i.e. amylin)\, would improve diabetes management. However\, formulation innovation is complicated by the poor stability of insulin monomers and amylin. Here\, I will discuss two polymeric excipient platforms (non-covalent PEGylation and amphiphilic copolymer excipients) that can be used to increase the stability of insulin in formulation and modulate insulin pharmacokinetics. Using these designer excipients\, I have developed three insulin formulations: (i) an ultrafast monomeric insulin lispro\, (ii) an insulin-amylin co-formulation and (iii) an ultrafast co-formulation. These enhanced insulin formulations are promising candidates to address formulation challenges related to achieving fully autonomous insulin delivery\, improve glucose control\, and reduce the burden of treatment management for patients with diabetes. URL:https://bme.utoronto.ca/event/designer-polymer-excipients-to-enable-next-generation-insulin-formulations/ LOCATION:MS2172 CATEGORIES:BME Faculty Search END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220621T120000 DTEND;TZID=America/Toronto:20220621T130000 DTSTAMP:20220621T153842Z CREATED:20220520T150058Z LAST-MODIFIED:20220621T153842Z UID:10000024-1655812800-1655816400@bme.utoronto.ca SUMMARY:Global Speaker Series: Gilbert Bernier\, PhD - Université de Montréal DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians.\nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Gilbert Bernier\, PhD\, Associate Professor in the Department of Neuroscience at Université de Montréal.\nThe title of this talk will be\, “Cone photoreceptor sheet transplantation for the treatment of macular degenerations”\nRegister now\nHybrid event\, with in-person and virtual options\nIn-person will be held at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.\nVirtual event links will be sent after registration. \nMore About Gilbert bernier:\nProfessor Gilbert Bernier performed is graduated studies in Molecular Biology at Montreal University where he characterized the gene mutated in the mouse neurological disorder dystonia musculorum. In 1997\, he moved to the Max-Planck Institute of Biophysical Chemistry in Germany to study developmental biology of the retina. Since 2001\, he is heading the laboratory of stem cell and developmental biology at Maisonneuve-Rosemont Hospital to exploit the potential of human pluripotent stem cells for the study and treatment of neurodegenerative diseases such as retinal degenerative diseases and Alzheimer’s disease. Professor Bernier has also contributed to the characterization of Polycomb group proteins function in brain cancer\, DNA repair\, and premature ageing. He is Professor at the Neuroscience Department of Montreal University since 2012. He is co-founder and CEO of StemAxonTM\, a Canadian corporation involved in the development of new treatments for neurodegenerative diseases.\n Learn more about Gilbert Bernier URL:https://bme.utoronto.ca/event/global-speaker-series-gilbert-bernier-phd-universite-de-montreal/ LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada CATEGORIES:External Speaker Series END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220621T110000 DTEND;TZID=America/Toronto:20220621T120000 DTSTAMP:20220603T151630Z CREATED:20220603T151630Z LAST-MODIFIED:20220603T151630Z UID:10000028-1655809200-1655812800@bme.utoronto.ca SUMMARY:Insights from the Endotronix Journey: A PMA Medtech “Startup" Story DESCRIPTION:Please join us for an ECHO webinar on Tuesday June 21\, 2022 (11 am – 12 pm EST) featuring Dr. Harry Rowland (CEO and Co-founder\, Endotronix). Dr. Rowland’s presentation entitled\, “Insights from the Endotronix Journey: A PMA Medtech “Startup” Story”\, will feature an overview of Endotronix\, its technologies and the story behind its success. Endotronix is a medical technology company\, delivering an integrated platform that provides comprehensive\, reimbursable health management innovations for patients suffering from advanced heart failure. Please see attachment for more details. \n\nRegister in advance for this webinar: https://us02web.zoom.us/meeting/register/tZwkc-GrqD0sGtcnluN7KLI2wNtAxZ1kYIx9 \nAfter registering\, you will receive a confirmation email containing information about joining the webinar. \n  \nECHO is an entrepreneurship training program\, funded and organized in a partnership between (i) the Translational Biology and Engineering Program (TBEP)\, the University of Toronto component of the Ted Rogers Centre for Heart Research\, and (ii) the Health Innovation Hub (H2i). URL:https://bme.utoronto.ca/event/insights-from-the-endotronix-journey-a-pma-medtech-startup-story/ CATEGORIES:External Speaker Series ORGANIZER;CN="Translational Biology and Engineering Program (TBEP)":MAILTO:reception.tbep@utoronto.ca END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220615T183000 DTEND;TZID=America/Toronto:20220615T223000 DTSTAMP:20220511T144914Z CREATED:20220510T201717Z LAST-MODIFIED:20220511T144914Z UID:10000009-1655317800-1655332200@bme.utoronto.ca SUMMARY:BME Dinner Reception DESCRIPTION:The 2022 BME Dinner Reception will be hosted at the Royal Ontario Museum to celebrate the achievements of graduate students.\n\n\nBME would like to invite you to the dinner reception at the Royal Ontario Museum (ROM). It has been a crazy last two years and it is a great time for us to get together\, celebrate our achievements\, and meet each other. Students\, faculty\, post-doc\, and administrators will be attending the event. \nThis dinner is free of charge to BME students\, staff\, core faculty members\, and primary cross-appointment faculty members. This will also be extended to non-BME students in core faculty member labs\, research associates in core faculty member labs\, and post-doctoral fellows in core faculty member labs. URL:https://bme.utoronto.ca/event/bme-dinner-reception/ LOCATION:Royal Ontario Museum\, 100 Queens Park\, Toronto\, ON\, M5S 2C6\, Canada CATEGORIES:Events & Workshops ATTACH;FMTTYPE=image/jpeg:https://bme.utoronto.ca/wp-content/uploads/2022/05/e425f089dea4fd7f064a4978a6ca7003-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220615T083000 DTEND;TZID=America/Toronto:20220615T170000 DTSTAMP:20220511T144921Z CREATED:20220510T210137Z LAST-MODIFIED:20220511T144921Z UID:10000011-1655281800-1655312400@bme.utoronto.ca SUMMARY:Toronto Biomedical Engineering Conference 2022 DESCRIPTION:Speakers\n \n  \n\nDr. Michael Snyder\n\nStanford University\n\nMichael Snyder is a Professor and Chair of the Department of Genetics and Director of the Center for Genomics and Personalized Medicine at Stanford University. He is a leader in the field of functional genomics and proteomics and a major participant of the ENCODE project. He is a co-founder of many companies including Personalis\, SensOmics\, Qbio\, January AI\, Filtricine\, Mirvine\, Protos\, Protometrix and Affomix and he is the author of the book “Genomics and Personalized Medicine: What Everyone Needs to Know”. \n\n\n\n\n\n\n\n\n\n\n\n\nDr. Nancy Allbritton\n\n\nUniversity of Washington\n\nDr. Nancy L. Allbritton joined the University of Washington as the Frank & Julie Jungers Dean of Engineering in November 2019. In that capacity\, she serves as the chief academic officer of the college and provides leadership to over 279 faculty and more than 8\,000 students. The College of Engineering is a top-15 nationally ranked public university program with annual research expenditures exceeding $159 million. \nAllbritton is an international expert on multiplexed single-cell assays\, microfabricated platforms for high-content cytometry combined with cell sorting\, and microengineered stem-cell-based systems for recapitulating human organ-level function. Four companies have been formed based on her research discoveries: Protein Simple (acquired by Bio-Techne in 2014)\, Intellego\, Cell Microsystems\, and Altis Biosystems. Allbritton holds an appointment in the UW’s Department of Bioengineering.  She has been nationally recognized for her research and is a Fellow of the American Association for the Advancement of Science\, the American Institute for Medical & Biological Engineering and the National Academy of Inventors. \nPrior to joining the UW\, Allbritton led the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University which spans two universities and three colleges. \n\n\n\n\n\n\n\n\nDr. Andrew Tsourkas\n\nUniversity of Pennsylvania\n\n\nAndrew Tsourkas\, Ph.D. is a Professor and Undergraduate Chair of Bioengineering at the University of Pennsylvania.  He received his Bachelor’s degree in Mechanical Engineering in 1997 from Cornell University and his Ph.D. in Biomedical Engineering from the Georgia Tech/Emory University joint Ph.D. program in 2002.  He conducted a post-doctoral fellowship in the Department of Radiology at Harvard University\, before joining Penn in 2004. Dr. Tsourkas is currently the Co-Director for the Center for Targeted Therapeutics and Translational Nanomedicine as well as the Chemical and Nanoparticle Synthesis Core. He was a recipient of the Coulter Foundation Early Career Award\, the National Science Foundation CAREER Award\, and was elected fellow of the American Institute for Medical and Biological Engineering. \n\n\n\n\n\n\n\n\n  \n\n\nSchedule\n\n\n\n\nTime\n\n\nActivity\n\n\n\n\n\n\n8:30 – 9:00 AM\n\n\nBreakfast\n\n\n\n\n9:00 – 9:15 AM\n\n\nWelcome from BME Director and ToBE Co-Chairs\n\n\n\n\n9:15 – 10:15 AM\n\n\nFirst Keynote Speaker\n\n\n\n\n10:30 – 11:15 AM\n\n\nWorkshop\n\n\n\n\n\n(1) Mindfulness Moment – Managing Anxiety in Graduate School\n\n\n\n\n\n(2) Building Resilience and Navigating Uncertainty in Graduate School\n\n\n\n\n11:30 – 12:30 PM\n\n\nPoster Session\n\n\n\n\n12:00 – 1:00 PM\n\n\nLunch\n\n\n\n\n1:00 – 2:00 PM\n\n\nOral Presentations\n\n\n\n\n\n(1) Clinical Engineering\n\n\n\n\n\n(2) Cell and Tissue Engineering\n\n\n\n\n\n(3) Molecular Engineering\n\n\n\n\n2:15 – 3:15 PM\n\n\nSecond Keynote Speaker\n\n\n\n\n3:30 – 4:30 PM\n\n\nThird Keynote Speaker\n\n\n\n\n4:30 – 4:45 PM\n\n\nClosing Remarks\n\n\n\n\n6:30 – 10:30 PM\n\n\nPost-Conference Celebration Dinner and Award Ceremony\n\nThe Royal Ontario Museum URL:https://bme.utoronto.ca/event/toronto-biomedical-engineering-conference-2022/ CATEGORIES:Events & Workshops ORGANIZER;CN="Toronto Biomedical Engineering Conference (ToBE)":MAILTO:tobeconferenceteam@gmail.com END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220614T130000 DTEND;TZID=America/Toronto:20220614T140000 DTSTAMP:20220609T150017Z CREATED:20220609T144415Z LAST-MODIFIED:20220609T150017Z UID:10000046-1655211600-1655215200@bme.utoronto.ca SUMMARY:Faculty Search Candidate Talk DESCRIPTION:This event will be in person only. URL:https://bme.utoronto.ca/event/faculty-search-talk-2-2022/ LOCATION:MS3153 CATEGORIES:BME Faculty Search END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220609T160000 DTEND;TZID=America/Toronto:20220609T170000 DTSTAMP:20220606T140220Z CREATED:20220606T140220Z LAST-MODIFIED:20220606T140220Z UID:10000029-1654790400-1654794000@bme.utoronto.ca SUMMARY:Re-purposing imaging contrast agents for targeted cancer treatment - Princess Margaret Seminar Series DESCRIPTION:Dr. Xiaohu Gao \nProfessor \nDepartment of Bioengineering and the Center for Nanotechnology \nUniversity of Washington| \n  \nPrincess Margaret Cancer Centre \nDr. Bob Bell Auditorium\, 6th Floor\, 6-604 \nJoin on MS Teams \n  \n*PLEASE NOTE: The seminar will be delivered live in-person at Princess Margaret Cancer Centre\, 6th floor Bob Bell Auditorium\, 610 University Ave and broadcasted via MS TEAMS.\nThose attending the in-person seminar must wear a mask and no food or drink will be permitted. All attendees must be fully vaccinated to enter the hospital. \n  URL:https://bme.utoronto.ca/event/re-purposing-imaging-contrast-agents-for-targeted-cancer-treatment-princess-margaret-seminar-series/ CATEGORIES:External Speaker Series END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220609T130000 DTEND;TZID=America/Toronto:20220609T150000 DTSTAMP:20220609T152227Z CREATED:20220511T143904Z LAST-MODIFIED:20220609T152227Z UID:10000014-1654779600-1654786800@bme.utoronto.ca SUMMARY:Spotlight on Clinical Translation: Making the leap from the lab bench to Phase I Clinical Trials DESCRIPTION: \nJoin us for Spotlight on Clinical Translation: Making the leap from the lab bench to Phase I Clinical Trials\, hosted by The Stem Cell Network and Medicine by Design.\nThis workshop will provide investigators and trainees with a basic understanding of the clinical pipeline\, from essential pre-clinical studies to Phase I first in human trials. The invited speakers will review processes involved in clinical trial submission\, regulatory approval and product manufacturing. An interactive Q&A session will ensure participants can ask questions relevant to their research along with leveraging this opportunity to connect with clinical trial experts.\nClinical studies are a key element on the pathway of translational cell and gene therapies. It is\, therefore\, essential that principal investigators\, researchers\, trainees\, clinical research fellows and ecosystem partners working in Canada undertaking translational research have a thorough understanding of the clinical trial pipeline; focused specifically on the early phase clinical trial design processes.\nRegister now!\nRegistration deadline:\nAttendance at this event is limited; all those interested in participating must register by June 8\, 2022\, at 11:59 PM local time.\nView Agenda\n1:00-1:05 pm ET – Opening Remarks\nModerators: Harold Atkins and Darshan Brahmbhatt\n1:05-1:40 pm ET – Presentation by Natasha Kekre\, MD\, Hematologist\, The Ottawa Hospital Transplant and Cellular Therapy Program\, and Scientist\, Ottawa Hospital Research Institute\nPresentation title: Building the pre-CTA and CTA package for Phase I trials: Case study using CLIC CAR-T trial for relapsed/refractory CD19 positive hematologic malignancies\n1:45-2:10 pm ET – Presentation by Patrick Bedford\, MSc\, Managing Director\, weCANreg Consulting Group Inc.\nPresentation title: Leveraging a regulatory rerspective on your path to trials\n2:15-2:40 pm ET – Presentation by Linh Nguyen\, PhD\, Staff Scientist/Head\, Cell Manufacturing Team\, Tumor Immunotherapy Program\, Princess Margaret Cancer Centre\nPresentation title: Developing a cell manufacturing process for an early phase clinical trial\n2:40-2:45 pm ET – Break\n2:45-3:00 pm ET – General Discussion/Q&A session\n3:00 pm ET – Closing Remarks\nSpeaker and Chair Details\nSPEAKERS\nPatrick BedfordNatasha KekreLinh NguyenPatrick Bedford\nPatrick Bedford\, MSc – Managing Director\, weCANreg Consulting Group Inc.\nPatrick Bedford is an experienced and certified regulatory professional who is focused on facilitating global regenerative medicine development. He founded & operates weCANreg Consulting Group Inc.\, which provides regulatory strategy\, interaction\, and submission services. Furthermore\, Patrick is VP of Regulatory & Development at Artisan Bio\, which is a CRISPR-enabled multiplex cell engineering company making precision immunotherapies. In his spare time\, he remains an active educator and contributor to regulatory policy development.\nPrior to incorporating his own company and leading regulatory strategy at Artisan Bio\, Patrick developed regulatory consulting services for a regenerative medicine Network Centre of Excellence; planned 2 Canadian CAR-T New Drug Submissions; and led teams at Health Canada responsible for developing guidance for biosimilars\, transplant material\, and cell & gene therapies. While leading these policy initiatives at Health Canada\, Patrick also supported their Therapeutic Products Classification Committee; chaired the Cells\, Tissues\, and Organs Classification Committee; and championed international harmonization initiatives.\nPatrick completed an Honours Bachelor of Health Sciences degree at the University of Western Ontario\, a Master’s degree in Bioethics and Health Law at the University of Otago\, a Regulatory Affairs Certificate from the Regulatory Affairs Professional Society\, and is pursuing his MBA at the Jack Welch Management Institute.\nNatasha Kekre\nNatasha Kekre\, MD – Hematologist\, The Ottawa Hospital Transplant and Cellular Therapy Program\, and Scientist\, Ottawa Hospital Research Institute \nDr. Natasha Kekre has been appointed to the Department of Medicine in the Division of Hematology\, within the Transplant and Cellular Therapy Program at The Ottawa Hospital\, effective October 2015. She is also an associate scientist within the Ottawa Hospital Research Institute and an associate professor of medicine at the University of Ottawa. She completed her Bachelor’s in Science at the University of Windsor then obtained her medical degree from the University of Ottawa. She then trained at the University of Ottawa in Internal Medicine and Hematology. She went on to do a fellowship in stem cell transplantation at Dana Farber Cancer Institute in Boston\, MA with a Masters in Public Health from Harvard University.\nHer research is focused on developing early phase clinical trials and moving home grown therapeutic strategies into patients. She collaborates with a number of local investigators and scientists in Ottawa\, studying hematologic malignancies and blood and marrow transplant recipients more specifically. She collaborates with scientists and physicians across Canada to build a Canadian CAR-T cell platform (chimeric antigen receptor T cells are immune cells engineered to kill cancer cells)\, bringing this exciting new therapy to Canadian patients. Her other clinical research interests include improving transplant related outcomes and projects with an epidemiologic focus\, including but not limited to decision modeling and meta-analyses.\nShe also participates with a number of cooperative groups in North America including the Center for International Blood and Marrow Transplant Research\, the Canadian Blood and Marrow Transplant Group\, the American Society of Hematology and the American Society for Transplant and Cellular Therapy.\nLinh Nguyen\nLinh Nguyen\, PhD – Staff Scientist/Head\, Cell Manufacturing Team\, Tumor Immunotherapy Program\, Princess Margaret Cancer Centre\nDr. Linh Nguyen has led the Cell Manufacturing Team of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre since 2005. Dr. Nguyen obtained her PhD in Immunology at the University of Toronto and pursued postdoctoral studies at Harvard Medical School. Her interests include tumor immunology and immunotherapy. Her team has manufactured cell and gene therapy products for clinical trials such as tumor-infiltrating lymphocytes (TILs)\, dendritic cells and T cell receptor gene-engineered T cells. The team’s activities also include quality assurance\, quality control\, and preparation of regulatory submissions. \nCHAIR\nHarold AtkinsDarshan H. BrahmbhattHarold Atkins\nHarold Atkins\, MD – Attending Physician\, The Ottawa Hospital Transplant and Cell Therapy Program\, and Scientist\, Ottawa Hospital Research Institute\nDr. Harry Atkins is a physician of The Ottawa Hospital Transplant and Cell Therapy Program\, an Associate Professor of Medicine at the University of Ottawa\, and a scientist in the Ottawa Hospital Research Institute’s Center for Innovative Cancer Research.\nHe received his Bachelor of Medical Science degree and Medical Degree from the University of Ottawa followed by a rotating internship year at the Victoria General Hospital in Victoria BC. Specialty training in Internal Medicine was done at the University of Ottawa. Clinical and research fellowships in Hematology\, Stem Cell Transplantation and Experimental Hematology followed at the University of Washington and at the Ontario Cancer Institute.\nHe specializes in hematopoietic stem cell transplantation and has spearheaded the use of stem cell transplantation for immune repair to treat patients with severe autoimmune diseases including multiple sclerosis\, scleroderma\, myasthenia gravis and others. The outcome of a trial using autologous hematopoietic stem cell transplantation to treat multiple sclerosis was published in the Lancet in 2016. He ran a clinical trial exploring the role of hematopoietic stem cell transplantation in preventing organ transplant rejection. He is a member of a BiocanRx funded\, pan-Canadian consortium to develop and improve the accessibility of new chimeric antigen receptor T lymphocytes for the treatment o URL:https://bme.utoronto.ca/event/spotlight-on-clinical-translation-making-the-leap-from-the-lab-bench-to-phase-i-clinical-trials/ LOCATION:Virtual CATEGORIES:Events & Workshops,External Speaker Series END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220608T190000 DTEND;TZID=America/Toronto:20220608T200000 DTSTAMP:20220527T201730Z CREATED:20220527T201730Z LAST-MODIFIED:20220527T201730Z UID:10000027-1654714800-1654718400@bme.utoronto.ca SUMMARY:Special session with EngSci alumnus Dr. Amir Manbachi: Towards building a clinically oriented Ultrasound Hub—The journey of an EngSci immigrant to academia DESCRIPTION:Dr. Amir Manbachi (EngSci 0T8\, BME MAsc 1T0\, PhD 1T5) founded the HEPIUS Innovation Lab\, focusing on the next generation of wearables and implantable medical ultrasound devices for spinal cord injury patients.  Join him for an interactive session where he’ll describe his journey from EngSci to his current position at Johns Hopkins University. URL:https://bme.utoronto.ca/event/special-session-with-engsci-alumnus-dr-amir-manbachi-towards-building-a-clinically-oriented-ultrasound-hub-the-journey-of-an-engsci-immigrant-to-academia/ CATEGORIES:External Speaker Series ATTACH;FMTTYPE=image/png:https://bme.utoronto.ca/wp-content/uploads/2022/05/Manbachi_June_2022.png ORGANIZER;CN="Engineering Science":MAILTO:engsci@utoronto.ca END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220601T120000 DTEND;TZID=America/Toronto:20220601T130000 DTSTAMP:20220520T151856Z CREATED:20220520T151856Z LAST-MODIFIED:20220520T151856Z UID:10000025-1654084800-1654088400@bme.utoronto.ca SUMMARY:Modern Toothpaste Technologies: The Role and Use of Hydroxyapatite in Oral Care DESCRIPTION:Faculty of Dentistry Research Seminar\nDr. Joachim Enax and Dr. Frederic Meyer\nDr. Kurt Wolff GmbH & Co. KG\,\nBielefeld\, GERMANY\nOver the last years synthetic hydroxyapatite has gained increasing attention as a biomimetic/bionic\noral care agent in preventive dentistry due to its high similarity to human tooth enamel. A significant\nand constantly increasing number of published studies demonstrate its efficacy in various fields of\npreventive oral health care. Currently\, both professional and public debate propagates\nhydroxyapatite as a viable biomimetic alternative to the long-established fluoride in oral care. For\nexample\, hydroxyapatite – in contrast to fluorides – can be used as safe and efficient ingredient for\nkids’ toothpastes because it is safe if swallowed and does not present any risk of fluorosis.\nThe presentation will cover the following topics: \n– Modern toothpaste technologies\, toothpaste ingredients and their functions\n– Hydroxyapatite in oral care\n– Synthesis\, characterization\, safety\, and application fields in dentistry\n– Mechanistic studies (in situ\, in vitro): SEM\, TEM\, TMR etc.\n– Modes of action\n– Clinical studies: RCTs on caries prevention\, gingival health\, reduction of dentin hypersensitivity URL:https://bme.utoronto.ca/event/modern-toothpaste-technologies-the-role-and-use-of-hydroxyapatite-in-oral-care/ LOCATION:Dentistry Building\, The auditorium (DN 19)\, 124 Edward Street\, 124 Edward Street\, Toronto\, Ontario\, Canada CATEGORIES:External Speaker Series END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220531T130000 DTEND;TZID=America/Toronto:20220531T140000 DTSTAMP:20220609T150149Z CREATED:20220525T131335Z LAST-MODIFIED:20220609T150149Z UID:10000026-1654002000-1654005600@bme.utoronto.ca SUMMARY:Faculty Search Candidate Talk DESCRIPTION:This event will be in person only. URL:https://bme.utoronto.ca/event/faculty-search-candidate-talk/ LOCATION:Medical Science Building\, Room 3153\, 1 King's College Circle\, Toronto\, Ontario\, M5S 1A8\, Canada CATEGORIES:BME Faculty Search END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220531T110000 DTEND;TZID=America/Toronto:20220531T120000 DTSTAMP:20220510T195824Z CREATED:20220510T192503Z LAST-MODIFIED:20220510T195824Z UID:10000008-1653994800-1653998400@bme.utoronto.ca SUMMARY:Reimagining the Jugular Venous Pressure: The Evolution of a Medical Technology Start-up DESCRIPTION:Please join us for an ECHO webinar on Tuesday May 31\, 2022 (11 am – 12 pm EST) featuring Dr. Andrew J Smith (CSO and Co-Founder\, JVPLabs). Dr. Smith’s presentation entitled\, “Reimagining the Jugular Venous Pressure: The Evolution of a Medical Technology Start-up”\, will feature an overview of JVPLabs\, its technologies and the story behind its success. JVPLabs is a medical device company founded in 2016 by two physicians\, Dr. Andrew Smith (Emergency Medicine) and Dr. Jason Roberts (Cardiology). The focus of the company is to develop a leading edge non-invasive technology to improve and enable assessment of Congestive Heart Failure (CHF) patients via the JVP height\, in hospital and remotely\, at home. Please see attachment for more details. URL:https://bme.utoronto.ca/event/reimagining-the-jugular-venous-pressure-the-evolution-of-a-medical-technology-start-up/ CATEGORIES:External Speaker Series ATTACH;FMTTYPE=image/jpeg:https://bme.utoronto.ca/wp-content/uploads/2022/05/thumbnail_ECHO-Webinar-Andrew-J-Smith-JVPLabs-May-31-2022-Social-media-e1652210852247.jpg ORGANIZER;CN="Translational Biology and Engineering Program (TBEP)":MAILTO:reception.tbep@utoronto.ca END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220530T150000 DTEND;TZID=America/Toronto:20220530T170000 DTSTAMP:20220530T152312Z CREATED:20220511T143954Z LAST-MODIFIED:20220530T152312Z UID:10000015-1653922800-1653930000@bme.utoronto.ca SUMMARY:Pitch Competition: Building a Biotech Venture program DESCRIPTION: \nRegister to join the audience at the 2022 Pitch Competition!\nJoin us in-person on May 30 for the Building a Biotech Venture Pitch Competition to learn how the next generation of regenerative and precision medicine researchers are preparing to translate their discoveries toward impact.\nWatch as six trainee-led teams from the University of Toronto and its affiliated hospitals pitch their ventures to an expert panel of judges. The winning team will receive $25\,000\, and the second-place team will receive $10\,000 in research funding to advance their product concept.\nRegister now\nThe competition is the culmination of Medicine by Design’s Building a Biotech Venture program\, offered in partnership with Precision Medicine Initiative (PRiME)\, the Health Innovation Hub (H2i) and Talk Boutique. Over the last six months\, teams have worked with mentors to advance early-stage company concepts based on their research.\nCome cheer on these up-and-coming entrepreneurs as they showcase their innovative technologies!\nNOTE: This event will be held in-person in accordance with the University of Toronto’s COVID-19 policies. Masks are required in indoor spaces where physical distancing cannot be maintained.\nMeet the judges\nAlberto GalassoElla Korets-Smith Angela MacDonaldRobin QuirkAlberto Galasso \n \nAlberto Galasso\, PhD\nProfessor of Strategic Management\nRotman School of Management\, University of Toronto\nRead more\nElla Korets-Smith\nElla Korets-Smith\, MBA\, MSc\nChief Business Officer\, Virica Biotech\nRead more\nAngela MacDonald\nAngela McDonald\, PhD\nEntrepreneur-in-Residence\, Versant Ventures\nRead more\nRobin Quirk\nRobin Quirk\, PhD\, MBA\nVice President\, Technology Sourcing & Venture Development\, CCRM\nRead more\nMeet the teams\nAzane Therapeutics\nDelivering the promise of RNA therapy.\nLab: Institute of Biomedical Engineering and Department of Immunology\, University of Toronto\nThis company’s product\, a delivery vehicle for mRNA-based therapies\, has the potential to make it possible for rare diseases to be treated with mRNA. The platform could also apply to regenerative medicine treatments such as stem cell reprogramming and inflammatory disorders.\nDTPX Therapeutics\nDeveloping immunotherapy against hibernating drug tolerant cancer cells for colorectal cancer patients.\nLab: Princess Margaret Cancer Centre\, University Health Network; and Donnelly Centre for Cellular and Biomolecular Research\, University of Toronto.\nWhen individuals are treated for colorectal cancer with standard chemotherapy\, a cell population that’s resistant to treatment can “hibernate” and re-emerge after treatment\, causing the tumour to relapse. DTXP Therapeutics aims to create a platform that can selectively target these hibernating cells to reduce the chance of relapse\, potentially benefiting many types of cancer. \nGlusyn Diagnostics\nAutomated PCR-free diagnostic systems for rapid\, low-cost\, distributed usage.\nLab: Leslie Dan Faculty of Pharmacy\, University of Toronto.\nWith mastitis in dairy cows as a use-case\, this teams aims to develop automated PCR-free diagnostic systems that are shelf-stable and have low manufacturing costs. \nA2O\nReprogramming for recovery.\nLab: Division of Anatomy\, University of Toronto.\nA2O has developed a type of gene therapy to convert toxic brain cells back into healthy cells to treat chronic neurodegenerative disease such as multiple sclerosis and Alzheimer’s disease\, as well as acute neurological injuries such as spinal cord injury. This therapy allows for a targeted approach that can be tailored to disease type\, stage or severity. \nOne Drug\nEnabling next generation drugs.\nLabs: Leslie Dan Faculty of Pharmacy\, University of Toronto; Institute of Biomedical Engineering\, University of Toronto; and Department of Chemistry\, University of Toronto. \nDeveloping clinical point-of-care diagnostic devices that will enable clinicians and drug developers identify patients at risk of adverse drug reactions and/or suboptimal drug response based on their genetic makeup. \nScivance\nDeveloping therapeutics for rare disease.\nLab: Department of Chemical & Physical Sciences\, University of Toronto Mississauga\nOnly five percent of rare diseases have treatments\, and a substantial portion of these rare diseases are caused by genes called fusion oncogenes. This team is developing a proprietary algorithm and multi-disciplinary pipeline which lies at the intersection of medicinal chemistry\, structural biophysics and molecular biology\, which can help develop treatments for these disease drivers. URL:https://bme.utoronto.ca/event/pitch-competition-building-a-biotech-venture-program/ LOCATION:Leslie Dan Pharmacy Building Room PB B250\, 144 College St\, Toronto\, M5S 3M2\, Canada CATEGORIES:Events & Workshops END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220519T090000 DTEND;TZID=America/Toronto:20220519T170000 DTSTAMP:20220511T185830Z CREATED:20220511T185830Z LAST-MODIFIED:20220511T185830Z UID:10000016-1652950800-1652979600@bme.utoronto.ca SUMMARY:Engineering Research Day 2022: Building a Sustainable Future DESCRIPTION:A hybrid event presented by U of T Engineering \nJoin us on Thursday\, May 19\, 2022 9:00 am – 5:00 pm for U of T Engineering’s second annual Engineering Research Day. This year’s theme of Building a Sustainable Future spotlights the unique role engineering professionals play in building a brighter future for all and celebrates the local and global impacts of \nU of T Engineering’s sustainability-focused research accomplishments and collaborations. \nThis event is open to all students\, alumni\, staff and faculty at U of T Engineering\, as well as current and \nprospective partners and key stakeholders across the research ecosystem. Through virtual and \nin-person programming\, Engineering Research Day 2022 offers an unparalleled opportunity to learn\, \nexplore and connect. \nU of T Engineering continues to be Canada’s top-ranked engineering school and consistently ranks in the global top 20. Our faculty are international leaders in their fields\, innovative educators\, and dedicated \nmentors. U of T Engineering’s research strengths draw students and faculty from all over the world. \n\n \n“I am excited to welcome everyone to this year’s Engineering Research Day event – this year’s focus on \nSustainability crosses all disciplines of Engineering and will showcase how our researchers are driving impactful programs\, projects and initiatives\, not only here in Canada but globally. “  \n– Chris Yip\, Dean\, U of T Engineering \n\nThe program will feature: \n1. Interactive fireside chats with keynote speakers (hybrid) \n2. Panels on sustainability and resilience across different disciplines (hybrid) \n3. Student networking lunch (in-person only) \n4. Booths from U of T Engineering research centres and institutes (hybrid) \n5. Open networking reception (in-person only) \nEngaging panel sessions will include: \n\nPutting the Engineering in Environmental\, Social and Governance (ESG) Investing\nEngineering Resilient Healthcare Systems: Lessons from the Pandemic\nSustainable Talent: Educating the 21st Century Engineer\nClimate Positive & Sustainable Campus\n\n*In-person venue: Myhal Centre for Engineering Innovation & Entrepreneurship\, 55 St. George Street URL:https://bme.utoronto.ca/event/engineering-research-day-2022-building-a-sustainable-future/ CATEGORIES:Events & Workshops ATTACH;FMTTYPE=image/png:https://bme.utoronto.ca/wp-content/uploads/2022/05/FSf3ruFXsAY3urd.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220518T160000 DTEND;TZID=America/Toronto:20220518T170000 DTSTAMP:20220511T133755Z CREATED:20220511T132357Z LAST-MODIFIED:20220511T133755Z UID:10000012-1652889600-1652893200@bme.utoronto.ca SUMMARY:Jump Start Workshop: Accelerate Innovation in Precision Medicine DESCRIPTION:Event Date: Wednesday\, May 18th\, 2022; 4:00 – 5:00 pm \nThis event is hybrid\, and will be taking place on Zoom\, as well as in the Leslie Dan Faculty of Pharmacy Building in Room 850. \nRegistration required. \nDuring this session our panelists will discuss early activities that researchers should engage to accelerate innovation into technology development. Programs from Health Innovation Hub (H2I)\, University of Toronto Early-Stage Technology (UTEST) and Creative Destruction Lab (CDL) will be introduced and followed by a discussion panel. You will learn from real-world examples about where to start and how to build a technology development plan to accelerate your path towards successful fundraising and venture formation in academic settings. This session will provide insight on what to expect from an incubator or accelerator at UofT and how to gain an access to coaching\, professionals-in-residence\, and investors. This session aims to stimulate commercial thinking during research and discovery phase for everyone interested in drug\, device and platform development at UofT. \nThe goal of PRiME’s Jump Start series is to provide a comprehensive look into the essential steps involved in development of pre-clinical drugs\, devices\, and platform technologies. In the series we engage with experts to discuss important considerations to ensure success at each step of the development process. \nThese workshops are open to all Trainees and Principal Investigators at UofT. \n\n\n\n\nREGISTER HERE\n\n\n\n\nSpeakers\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  \n  \nHassan Jaferi\, MSc\nCo-Director\, UTEST \nHassan Jaferi is the Co-Director of the UTEST incubator jointly run by the University of Toronto and the Toronto Innovation Acceleration Partners. Hassan has been involved in the creation of multiple university startups and IP acquisition/acqui-hire deals. While working at UTEST\, Hassan is also the Chief Executive officer of Bitnobi\, Inc. which is a startup that has designed and developed a privacy protected\, data sharing platform. At Bitnobi\, Hassan manages all day-to-day business affairs for the company in order to help commercialize their solution. He holds an M.Sc from the International Space University and a BASc in Computer Engineering from the University of Ottawa. \n\n\n  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMathew Platt\, PhD\nAssociate Director\, Creative Destruction Lab \nMathew got his start at the University of Guelph with a PhD in Human Health and Nutritional Sciences following an undergraduate honors degree in Biomedical Sciences. A scientist by training\, his passions evolved through graduate school towards entrepreneurship and business development. These passions lead him to found the Guelph Chapter of the non-profit event-driven group called the Science to Business Network in the fall of 2018. After defending his PhD in early 2019\, Mathew explored his passion further as the Director of Business Development for the National Chapter of the Science to Business Network. It was through this position that he first learned about the Creative Destruction Lab (CDL) in Toronto. Hired first as a Venture Manager for the Health stream in February of 2020\, Mathew went on to hold positions as the Recruitment Lead for Health at Toronto\, the Site Venture Recruitment Lead\, the Stream Lead and Senior Venture Manager for Health\, and now the Associate Director of Health. Passionate about building bridges between academia and industry\, Mathew now leads the CDL-Toronto’s Health strategy for how to recruit and support science and technology-based health-tech startups. \n  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nJ. Paul Santerre\, PhD\nCo-director of the Health Innovation Hub (H2i) \nProfessor J. Paul Santerre has published >200 peer reviewed publications and is a listed inventor on >70 patents in the area of medical polymers\, biodegradation\, protein and blood interactions with surfaces\, surface modification\, regenerative medicine\, and drug delivery. He is co-founder and current director of the Health Innovation Hub at the University of Toronto (a student focused entrepreneur training co-curricular program with > 500 client health science and biomedical engineering start-up companies to date that have generated > $109MCdn). He is a co-founder of Interface Biologics and current CSO for the company\, along with being a co-founder of five other start-up companies\, and has won multiple national awards for his achievements in enabling entrepreneurship. These awards have included Canada’s Governor General award for Innovation\, and the Professional Engineers of Ontario Entrepreneurship Award in 2017. He has been awarded with the Baxter Chair for Health Technology & Commercialization at the University Hospital Network. He was president of the 2016 World Biomaterials Congress held in Montreal Canada\, and has received multiple awards for his community activity including the 2016 Community award from the Canadian Biomaterials\, the 2018 President’s Impact Award from the University of Toronto. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  \nJennifer Doucet\, PhD\nCo-Founder\, Glusyn \nJennifer joined Dr. Keith Pardee’s lab in October 2020 to work on the pandemic response projects to help automate the glucose meter sensing technology for point-of-need use in collaboration with NRC-CRAFT. Prior to joining the Pardee lab\, she was working as an industry scientist on validation of new In-vitro diagnostics (IVD) products and completed a PhD in the Cell and Systems Biology department at University of Toronto in 2018. Using the technology developed in the Pardee lab\, Jennifer co-founded Glusyn\, a company developing accurate and low-burden diagnostics through cell-free synthetic biology-based technology that allows for on-site testing of infectious diseases using a repurposed glucose meter as a convenient and universal reader for gene circuit sensor outputs. Glusyn has been a part of the UTEST 2021 cohort and became an H2i company through PRiME and Medicine By Design’s Building a Biotech Venture program in early 2022. The company is co-lead by Jennifer herself\, along with Evan Amalficano (PhD Candidate)\, Dr. Moiz Charania (Research Associate) and Dr. Keith Pardee in the Leslie Dan Faculty of Pharmacy at the University of Toronto. \n\n\n\n\n\n\n\n\n\nMODERATOR\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMilica Vukmirovic\nDirector\, External Programs & Partnerships\, PRiME \n\n\n\n\nREGISTER HERE URL:https://bme.utoronto.ca/event/jump-start-workshop-accelerate-innovation-in-precision-medicine/ CATEGORIES:Events & Workshops END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Toronto:20220517T120000 DTEND;TZID=America/Toronto:20220517T130000 DTSTAMP:20220517T143732Z CREATED:20220511T143904Z LAST-MODIFIED:20220517T143732Z UID:10000013-1652788800-1652792400@bme.utoronto.ca SUMMARY:Global Speaker Series: Klavs Jensen\, PhD - Massachusetts Institute of Technology DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians.\nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Klavs Jensen\, PhD\, Warren K. Lewis Professor\, Chemical Engineering\, and Professor\, Materials Science and Engineering\, Massachusetts Institute of Technology.\nThe title of this talk will be\, “Accelerating chemical development with automation and machine learning.”\n Register for this virtual event. \nMore About Klavs jensen:\nKlavs F. Jensen is Warren K. Lewis Professor in Chemical Engineering and Materials Science and Engineering at the Massachusetts Institute of Technology. From 2007- July 2015 he was the Head of the Department of Chemical Engineering. His research interests include on-demand multistep synthesis\, methods for automated synthesis\, and machine learning techniques for chemical synthesis and interpreting large chemical data sets. He is a co-director of MIT’s consortium\, Machine Learning for Pharmaceutical Discovery and Synthesis\, which aims to bring machine learning technology into pharmaceutical discovery and development. Professor Jensen is a member of the US National Academy of Sciences\, the US National Academy of Engineering as well as the American Academy of Arts and Science. He is a Fellow of the American Association for the Advancement of Science (AAAS)\, and the American Institute of Chemical Engineers\, and the Royal Society of Chemistry.\n Learn more about Klavs Jensen’s lab URL:https://bme.utoronto.ca/event/global-speaker-series-klavs-jensen-phd-massachusetts-institute-of-technology/ CATEGORIES:External Speaker Series END:VEVENT END:VCALENDAR